These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

656 related items for PubMed ID: 25916665

  • 1. Immunomodulatory therapies for relapsing-remitting multiple sclerosis: monoclonal antibodies, currently approved and in testing.
    Craddock J, Markovic-Plese S.
    Expert Rev Clin Pharmacol; 2015 May; 8(3):283-96. PubMed ID: 25916665
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of monoclonal antibody therapies for relapsing remitting multiple sclerosis: A network meta-analysis.
    Xu X, Chi S, Wang Q, Li C, Xu B, Zhang J, Chen X.
    Mult Scler Relat Disord; 2018 Oct; 25():322-328. PubMed ID: 30195200
    [Abstract] [Full Text] [Related]

  • 3. An update on new and emerging therapies for relapsing-remitting multiple sclerosis.
    Weinstock-Guttman B.
    Am J Manag Care; 2013 Nov; 19(17 Suppl):s343-54. PubMed ID: 24494635
    [Abstract] [Full Text] [Related]

  • 4. Safety of monoclonal antibodies for the treatment of multiple sclerosis.
    McGinley MP, Moss BP, Cohen JA.
    Expert Opin Drug Saf; 2017 Jan; 16(1):89-100. PubMed ID: 27756172
    [Abstract] [Full Text] [Related]

  • 5. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM, Carter JL.
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [Abstract] [Full Text] [Related]

  • 6. Novel and imminently emerging treatments in relapsing-remitting multiple sclerosis.
    Oh J, O'Connor PW.
    Curr Opin Neurol; 2015 Jun; 28(3):230-6. PubMed ID: 25887773
    [Abstract] [Full Text] [Related]

  • 7. Update on disease-modifying therapies for multiple sclerosis.
    Vargas DL, Tyor WR.
    J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
    [Abstract] [Full Text] [Related]

  • 8. Emerging injectable therapies for multiple sclerosis.
    Oh J, Calabresi PA.
    Lancet Neurol; 2013 Nov; 12(11):1115-26. PubMed ID: 24090587
    [Abstract] [Full Text] [Related]

  • 9. Advances in the treatment of relapsing-remitting multiple sclerosis.
    Tanasescu R, Ionete C, Chou IJ, Constantinescu CS.
    Biomed J; 2014 Nov; 37(2):41-9. PubMed ID: 24732658
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N, Yaldizli O, Mäurer M, Cursiefen S, Kuckert S, Klawe C, Maschke M, Tettenborn B, Limmroth V.
    Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
    [Abstract] [Full Text] [Related]

  • 11. High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis.
    Freeman L, Longbrake EE, Coyle PK, Hendin B, Vollmer T.
    CNS Drugs; 2022 Dec; 36(12):1285-1299. PubMed ID: 36350491
    [Abstract] [Full Text] [Related]

  • 12. Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies.
    Melzer N, Meuth SG.
    Clin Exp Immunol; 2014 Mar; 175(3):359-72. PubMed ID: 24032475
    [Abstract] [Full Text] [Related]

  • 13. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O'Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose JW, CHOICE investigators.
    Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
    [Abstract] [Full Text] [Related]

  • 14. Emerging therapies in relapsing-remitting multiple sclerosis.
    Marriott JJ, O'Connor PW.
    Rev Recent Clin Trials; 2010 Sep; 5(3):179-88. PubMed ID: 20500147
    [Abstract] [Full Text] [Related]

  • 15. Novel therapeutic options for multiple sclerosis.
    Curtin F, Hartung HP.
    Expert Rev Clin Pharmacol; 2014 Jan; 7(1):91-104. PubMed ID: 24325127
    [Abstract] [Full Text] [Related]

  • 16. Daclizumab for the treatment of relapsing-remitting multiple sclerosis.
    Herwerth M, Hemmer B.
    Expert Opin Biol Ther; 2017 Jun; 17(6):747-753. PubMed ID: 28286970
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Monoclonal antibodies in treatment of multiple sclerosis.
    Rommer PS, Dudesek A, Stüve O, Zettl UK.
    Clin Exp Immunol; 2014 Mar; 175(3):373-84. PubMed ID: 24001305
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.